Research Nester Logo.jpg
Nuclear Medicine Market revenue to surpass USD 20 Billion by 2033, says Research Nester
07 févr. 2024 05h30 HE | Research Nester
New York, Feb. 07, 2024 (GLOBE NEWSWIRE) -- The global nuclear medicine market size is predicted to expand at ~20% CAGR between 2023 and 2033. The market is projected to garner a revenue of USD 20...
BIORESTORATIVE logo.jpg
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022
29 nov. 2022 11h20 HE | BioRestorative Therapies, Inc.
MELVILLE N.Y., Nov. 29, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK...
Logo.png
BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference
27 sept. 2022 07h00 HE | BioRestorative Therapies, Inc
MELVILLE, NY., Sept. 27, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
Logo.png
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
30 juin 2022 07h30 HE | BioRestorative Therapies, Inc
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...
Logo.png
BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference
06 janv. 2022 06h00 HE | BioRestorative Therapies, Inc
MELVILLE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies,...
Logo.png
BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show
21 déc. 2021 06h00 HE | BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
Logo.png
BioRestorative Therapies Announces Closing of $23 Million Public Offering
09 nov. 2021 14h20 HE | BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
Be Humance
Be Humance Launches New Collection of Self-Care Essentials to Help De-Stress and Relax
28 oct. 2021 11h00 HE | Be Humance
LOS ANGELES, Oct. 28, 2021 (GLOBE NEWSWIRE) -- According to a recent survey conducted by the American Psychological Association (AMA), more than 80% of Americans report emotions associated with...
New.jpg
BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
26 oct. 2021 16h05 HE | BioRestorative Therapies, Inc
MELVILLE, NY, Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BRTX” or the “Company”) (OTC: BRTX), a life sciences company focused on adult stem cell-based therapies, today...
ritter.jpg
Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC
16 avr. 2020 14h07 HE | Ritter Pharmaceuticals, Inc.
Special Meeting of Ritter Pharmaceuticals, Inc. Stockholders to Vote on Proposed Merger Scheduled for May 14, 2020 LOS ANGELES , April 16, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....